TAVR: nemesis of NOACs?

Data on non-vitamin K antagonist oral anticoagulants (NOACs) in transcatheter aortic valve replacement (TAVR) patients are controversial. In patients without atrial fibrillation (AF), rivaroxaban showed enhanced ischemia and bleeding as compared to standard of care. ENVISAGE showed enhanced bleeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Polzin, Amin, Helten, Carolin, Metzen, Daniel, Zako, Saif, Veulemans, Verena, Kelm, Malte, Zeus, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925602/
https://www.ncbi.nlm.nih.gov/pubmed/36318378
http://dx.doi.org/10.1007/s11239-022-02721-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925602/
https://www.ncbi.nlm.nih.gov/pubmed/36318378
http://dx.doi.org/10.1007/s11239-022-02721-6

Ejemplares similares